|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | PhaseI pharma- cokinetie and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand recep- tor显示文摘 | Tolcher AW Mita M Meropol NJ etal | 2007 | J Clin Oncol2007，25，： | 1 |
| 2 | UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan显示文摘 | Carlini LE Meropol NJ Bever J | 2005 | Clin Cancer Res2005，11，： | 1 |
| 3 | Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer 显示文摘 | Goldberg RM Meropol NJ Tabemero J | 2009 | Castrointest Cancer Res2009，3，2： | 1 |
| 4 | Preliminary studies of a novel oral fluoropyrimidine carbamate:capecitabine显示文摘 | Budman DR Meropol NJ Reigner B | 1998 | J Clin Oncol1998，16，6： | 1 |
| 5 | Development of new agents for the treatment of advanced colorectal cancer 显示文摘 | Lewis NL Meropol NJ | 2003 | Clin Colorectal Cancer2003，3，： | 1 |
| 6 | Bevacizumab incombination with oxaliplatin, fluorouracil, and leucovorin (FOL2FOX4) for previously treated metastatic coloreetal cancer:resultsfrom the Eastern Cooperative Oncology Group Study E3200显示文摘 | Giantonio B J Catalano P J Meropol NJ | 2007 | J Clin Oncol2007，25，12： | 1 |
| 7 | Bevacizumab in combination with oxaliplatin fluorouracil,and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer:results from the Eastern Cooperative Oncology Group Study E3200显示文摘 | Giantonio BJ Catalano PJ Meropol NJ | | 0，，12： | 1 |
| 8 | Oral fluoropyrimidines in the treatment of colorectal cancer显示文摘 | Meropol NJ | | 0，，： | 1 |
| 9 | Colon cancer recurrence:insights from the interface between epidemiology,laboratory sci-ence,and clinical medicine显示文摘 | Meropol NJ Berger NA | | 0，，22： | 1 |
| 10 | Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel 显示文摘 | Rothenberg ML Meropol NJ Poplin EA | 2001 | J Clin Oncol2001，19，18： | 1 |
| 11 | Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘 | Saltz LB Meropol NJ Loehrer PJ Sr | 2004 | J Clin Oncol2004，22，7： | 1 |
| 12 | Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘 | Saltz L Meropol NJ | | 0，，： | 1 |
| 13 | Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘 | Saltz LB Meropol NJ Loehrer PJ Sr | 2004 | J Clin Oncol2004，22，7： | 1 |
| 14 | Ac- complishments in 2008 in the treatment of advaffced metastatic colorectal cancer显示文摘 | Goldberg RM Meropol NJ Tabernero J | 2009 | Gastrointest Cancer Res2009，3，2： | 1 |
| 15 | A phase I trial of es- calating doses of trastuzumab combined with daily subcutaneous interleukin 2:report of cancer and leukemia group B 9661 显示文摘 | Fleming GF Meropol NJ Rosner GL | 2002 | Clin Cancer Res2002，8，12： | 1 |
| 16 | Phase I pharmacokinetic and biologic correlative study of mapatumumab,a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1显示文摘 | Tolcher AW Mita M Meropol NJ | 2007 | J Clin Oncol2007，25，11： | 1 |
| 17 | Phase Ⅱ study of oral eniluacil 5-Fluorouracil and leucovorin in patients with advanced colorectat carcinom显示文摘 | Meropol NJ Hollis D | 2001 | Cancer2001，91，7： | 1 |
| 18 | Pharmacogenetic analysis of UGT1A1, UGT1A6, UGT1A7 and thymidylate synthase in a phase Ⅱ study of capecitabine plus irinotecan in patients with metastatic colorectal cancer显示文摘 | Carlini LE Meropol NJ Chen Y-M | 2004 | Proc Amer Soc Clin Oncol2004，23，： | 1 |
| 19 | Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor 显示文摘 | SALTZ LB MEROPOL NJ LOEHRER PJ SR | 2004 | J Clin Oncol2004，22，7： | 1 |
| 20 | Bevacizumab in combi- nation with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 显示文摘 | Giantonio BJ Catalano PJ Meropol NJ | 2007 | J Clin Oncol2007，25，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员